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  12 
Abstract 13 
Currently in the USA, one name is added to the organ transplant waiting list 14 
every 15 min. As this list grows rapidly, fewer than one-third of waiting patients 15 
can receive matched organs from donors. Unfortunately, many patients who 16 
require a transplant have to wait for long periods of time, and many of them die 17 
before receiving the desired organ. In the United States alone, over 100,000 18 
patients are waiting for a kidney transplant. However, it is a problem that affects 19 
around 6% of the word population. Therefore, seeking alternative solutions to 20 
this problem is an urgent work. Here we review the current promising 21 
regenerative technologies for kidney function replacement. Despite many 22 
approaches being applied in the different ways outlined in this work, obtaining 23 
an organ capable of performing complex functions such as osmoregulation, 24 
excretion or hormone synthesis is still a long-term goal. However, in the future 25 
the efforts in these areas may eliminate the long waiting list for kidney 26 
transplants, providing a definitive solution for patients with end-stage renal 27 
disease.  28 
 29 
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  33 
Introduction 34 
 35 
Currently, many patients are suffering degenerative processes or injuries which 36 
end in specific irreversible organ failure. In many instances, therapeutic options 37 
are limited to supportive measures and preventing further damage [1], but 38 
transplantation represents the ideal method of restoring full physiological organ 39 
function [2]. Paradoxically, the effectiveness of this treatment has used up many 40 
organs for transplant, and their availability has been the main limitation of the 41 
technique [3,2]. In the USA, one name is added to the organ transplant waiting 42 
list every 15 min [4]. While this list grows rapidly, fewer than one-third of waiting 43 
patients can receive matched organs from donors [5]. For this reason, many 44 
patients who require a transplant have to wait long periods of time and a lot of 45 
them die before receiving the desired organ [6]. Specifically, patients with 46 
advanced renal disease are habitually obliged to resort to renal replacement 47 
therapies alternative to transplant, such as haemodialysis, due to the long 48 
waiting list for a kidney. Nevertheless, more patients either die or are removed 49 
from the waiting list because of the progression of pathophysiological conditions 50 
such as coronary artery disease during prolonged haemodialysis [7]. Moreover, 51 
these techniques fail to meet the functional endocrine and reabsorption 52 
demands of normal kidney function [2], affecting the patient’s quality of life [8] 53 
and entailing a very high cost for public sanitary services. Currently, these costs 54 
could reach up to €1,518 million for countries like Spain or £1.2 billion in the 55 
United Kingdom [9, 10]. In the USA alone, more than 400,000 patients are 56 
suffering from end-stage kidney disease and the waiting list for a kidney 57 
extends to 100,000 individuals [11,12]. However, it is a problem that affects 58 
around 6% of the word population [13]. Thus, the global prevalence of chronic 59 
kidney disease is rising at an alarming rate, correlated with the high increase in 60 
prevalence of obesity, which is associated with type II diabetes and renal failure 61 
[14]. Even in Spain, a leading country in the field of transplantation, today 62 
approximately 129 (incidence) and 1039 (prevalence) patients per million 63 
habitants still require renal replacement therapies [9]. However, even in the 64 
event of getting a transplantable kidney, around 20% of recipients will 65 
experience an episode of acute rejection within 5 years of transplantation, and 66 
approximately 40% of recipients will die or lose graft function within 10 years 67 
after transplantation [15]. 68 
 69 
Regenerative medicine has garnered considerable attention in recent years 70 
because it has the potential to provide the ultimate treatment for various 71 
diseases by generating new organs for transplantation. However, the 72 
development of an organism involves not only differentiation of cells, but also 73 
their morphogenesis and appropriate patterning to form the architectural context 74 
of tissues and organs [16]. Thus, mammalian cells, as part of multicellular 75 
organisms, function in tissue units that contain several types of cells, which 76 
together form an organ. Essentially, to function adequately, cells need to 77 
communicate with each other and their microenvironment, by means of growth 78 
factors, morphogens, cell adhesion molecules and mechanoreceptors. 79 
Specifically, human kidney exhibits a remarkable architectural complexity, 80 
coupled with the presence of at least 30 different specialized cells [17]. Thus, 81 
recapitulation of complex functions such as glomerular filtration and 82 
reabsorption and secretion of solutes are dependent on a three-dimensionally 83 
integrated kidney structure, which is why cell therapies with individual cells are 84 
inefficient in restoring kidney function [18].  85 
 86 
However, the idea of generating a functional kidney graft in vitro on demand 87 
would extend the option of kidney transplantation to more patients. 88 
Furthermore, the use of autologous cells could eliminate the need for lifelong 89 
immunosuppressive therapy. In this line, the field of renal bioengineering is 90 
exploring new frontiers basing on biotechnology, bioengineering, stem cells and 91 
regenerative medicine in an attempt to obtain a renal organ able to function as 92 
well as a native kidney. Here, we review the latest developments in 93 
regenerative medicine strategies for generation of kidney grafts on demand, 94 
with a main focus on (a) stem cells; (b) blastocyst complementation; (c) 95 
decellularization/recellularization technology; (d) bioprinting in 3D; (e) renal 96 
device; (f) xenoembryos, and (g) transplantation of embryonic kidneys. 97 
 98 
 99 
Stem Cells  100 
 101 
Pluripotent stem cells (PSC) generally include both embryonic stem cells (ESC) 102 
and induced pluripotent stem cells (iPSC), which have the potential to 103 
differentiate into any cell type and self-assemble into heterogeneous tissues or 104 
organs. Through direct differentiation, PSC have originated several cell types or 105 
tissues, such as hepatic [19], neural [20], cardiac [21], pancreatic [22] and blood 106 
tissues [23]. In the case of the kidney, recent progress has generated human 107 
nephron progenitor cells, also including intermediate mesoderm and 108 
metanephric mesenchyme cells [24]. By sequential application of chemicals or 109 
growth factors, there are studies that differentiated in vitro PSC and generated 110 
cells with ureteric bud-committed intermediate mesoderm fate with the potential 111 
to assemble spontaneously [25] and which could generate renal structures such 112 
as nephrons and proximal tubules [26]. The co-culture of embryoid bodies 113 
(which contains nephron progenitors) with a mouse embryonic spinal cord (an 114 
inducer of kidney tubulogenesis), resulted in the formation of tubular renal 115 
structures with the characteristic markers of renal structures [26]. However, no 116 
mechanism by which to generate a vascular system around these renal 117 
structures is known, so urine output could not be demonstrated. 118 
 119 
However, the potential tumorigenicity of PSC is one limiting step in the future 120 
clinical application of this methodology. In this case, adult stem cells (ASC) 121 
receive great interest, as they are clinically safe, not being tumorigenic [24, 27]. 122 
These ASC have been isolated from many human tissues such as the 123 
intestines, muscles, skin, blood, nerves, heart, liver, dental pulp, adipose tissue, 124 
umbilical cord blood, amniotic fluid and endometrial tissue [28]. The ASC can 125 
divide by asymmetric division leading to two types of daughter cells, one of 126 
which is an identical parent cell mother involved in the process of self-renewal, 127 
while the other results in a transient cell amplification that proliferates to 128 
produce the various differentiated cell types required to maintain tissue 129 
homeostasis [28]. In the kidney, renal ASC are located in specific regions in the 130 
adult organ, such as in tubular epithelial cells [30], Bowman’s capsule [31], the 131 
renal papilla [32] and the S3 segment of the proximal tubules [33]. Using S3-132 
segment ASC, the reconstitution of a 3D kidney-like structure in vitro has been 133 
described [34]. However, as in the case of PSC, although the reconstructed 134 
kidney structure possesses glomeruli, proximal tubules, Henle’s loop, distal 135 
tubules and collecting ducts, it had no functional vasculature. Thus, non-136 
vascularized kidney structures did not produce urine. These results suggest that 137 
tissue-specific stem cells may only have the ability to reconstitute the minimum 138 
unit of its organ of origin by differentiating into specialized cells in the correct 139 
niche [24].  140 
 141 
However, although it is difficult to build a complex organ like the kidney using 142 
techniques based on individual cells, these cells may be a promising cellular 143 
source for kidney repair and regeneration. Furthermore, these cells could be 144 
used in the different gene-editing platforms that have recently emerged to 145 
increase homologous recombination efficiency. Thus, DNA nucleases and 146 
CRISPR/Cas9 have emerged as potential tools for gene editing to generate 147 
kidney disease animal models [35, 36] or to generate human reporter PSC lines 148 
that may help us in the dissection of the molecular cues that organize the renal 149 
differentiation and evaluate its maturity [37, 38]. 150 
 151 
 152 
Blastocyst Complementation 153 
 154 
At blastocyst, the initial embryonic stage 5 days after fertilization, the injected 155 
PSCs become synchronized with the development of inner cell mass, 156 
generating a chimeric body. Thus, injection of normal ESC into a deficient 157 
blastocyst results in the formation of a normal chimeric organism known as a 158 
blastocyst complementation phenomenon. This method uses the chimera-159 
forming ability of PSCs that are injected into a xenoblastocyst, which lacks 160 
potential to form any particular cell lineage. Thus, these cells lines are 161 
exclusively derived from exogenous normal PSC, which assume the role that 162 
deficient cells cannot accomplish due to the lack of any functional gene [39]. 163 
Employing this methodology for the first time, in 1993 Chen et al. injected 164 
normal ESC into the blastocyst unable to develop mature B or T lymphocytes 165 
[40]. Thus, somatic chimeras were generated with foreign ESC-derived mature 166 
B and T lymphocytes. However, this blastocyst complementation system was 167 
applied to reconstruct several different tissues and organs such as thymic 168 
epithelium [38], germ cells [41], heart [42], pancreas [43, 44], liver [45] and 169 
kidney [46]. Recently it has been reported that rat iPSC injected into a 170 
pancreatogenesis-disabled mouse blastocyst produced a normal chimeric 171 
mouse with almost entirely rat pancreas that produced insulin and whose 172 
pancreas islets improved hyperglycaemia when transplanted into a diabetic 173 
rodent model [43, 44, 47]. Similarly, blastocysts with a deficient blastocyst in 174 
fumarylacetoacetate hydrolase injected with normal mouse iPSC produced 175 
chimeric mice with a iPSC-derived liver whose hepatocytes had a proliferative 176 
capacity characteristic of normal hepatocytes [45]. These studies indicated that 177 
progeny derived from PSC could occupy and develop in a vacant 178 
developmental niche, a fact that could be used along with demonstrated 179 
interspecific blastocyst complementation to in vivo-generation of organs derived 180 
from donor PSC using a xenogeneic environment [24, 46, 47]. 181 
 182 
In the case of the kidney, deficient mice blastocyst in spalt-like transcription 183 
factor 1 (Sall1; a transcription factor essential in renal organogenesis) injected 184 
with mouse iPSC resulted in mice with kidneys almost entirely originated from 185 
the injected iPSC [44]. This is because, although the Sall1+ metanephric tissues 186 
are exclusively derived from iPSC, Sall1- tissues such as ureteric bud and 187 
nervous and vascular system are derived from the host. This may constitute an 188 
obstacle, as it could promote a tissue rejection response [39]. In fact, when 189 
normal rat iPSC where injected into Sall1-deficient mice blastocysts, the 190 
expected results were not achieved and the progeny did not possess kidneys 191 
derived from the rat iPSC [48]. Consequently, these findings could be an 192 
obstacle to the notion of generating a functional human kidney through 193 
blastocyst complementation employing a xenogeneic environment. Of course, 194 
this does not exclude that blastocyst complementation remains one of the most 195 
promising strategies for obtaining a whole functional kidney. 196 
 197 
 198 
Decellularization/Recellularization technology 199 
 200 
Natural or organ-derived biological scaffolds composed of extracellular matrix 201 
(ECM) are used for a variety of reconstructive surgical applications and are 202 
increasingly used in regenerative medicine strategies [49]. The biocompatibility 203 
with natural materials is obviously excellent [50] and it is important to note that 204 
the ECM is a secreted product of cells whose composition and ultrastructure are 205 
determined by several factors that influence the phenotype of these cells, such 206 
as mechanical forces, biochemical milieu, oxygen requirements, pH and the 207 
gene expression patterns [51]. Likewise, the ECM influences the behaviour and 208 
phenotype of the resident cells [49, 51]. That is to say that cell attachment, 209 
migration, proliferation and three-dimensional spatial arrangement are strongly 210 
affected by matrix composition (collagen, fibronectin, laminin, 211 
glycosaminoglycans and growth factors). The ECM plays a central role in 212 
mammalian development and physiology [51]. In fact, the amino acid sequence 213 
and quaternary structure of many components of ECM such as collagen are 214 
highly conserved across species. This sequence homology could function as a 215 
constructive scaffold in mammalian recipients, rather than inciting a destructive 216 
inflammatory reaction.  217 
 218 
Decellularization is a technique for obtaining natural scaffolds that could be 219 
used for recellularization [52, 53]. This methodology generally involves the 220 
perfusion of detergents, enzymes or other cell-lysing solutions through the 221 
organ vasculature to remove the cellular components while preserving the 3D 222 
architecture and biochemical composition of native ECM.  It has been reported 223 
that decellularized cadaveric scaffolds can provide a niche for stem cells to 224 
differentiate into an appropriate cell type that contributes to whole organ 225 
generation [54]. Employing this strategy, Ott et al. developed a functional 226 
artificial rat heart using a heart scaffold that retained its three-dimensional 227 
geometry and vasculature, whereby cardiac cells were perfused 228 
for recellularization [53]. This experiment results in a contractile myocardium. 229 
This methodology of decellularization before recellularization has also been 230 
employed to develop transplantable liver and lungs using mature hepatocytes 231 
and alveolar epithelial cells, respectively [55, 56].  232 
 233 
Following this strategy, several attempts were made to regenerate a kidney, as 234 
it is known that ECM plays a crucial role in kidney development and repair [2, 235 
24]. After decellularization, kidney scaffolds have been shown to preserve the 236 
glomerular and tubular architecture and the vascular network [57]. This 237 
structuration retains renal-specific biochemical and biophysical cues that are 238 
able to modulate cell proliferation and differentiation, with a regional-specific 239 
effect on stem cell behaviour. In 2013 Song et al. reported successful whole 240 
kidney regeneration, which may produce urine after transplantation [15]. They 241 
used cadaveric kidneys from rats, pigs and humans to produce acellular renal 242 
scaffolds by decellularization solution perfusion. Then, these scaffolds were 243 
repopulated by perfusion of endothelial and epithelial cells, leading to the 244 
formation of viable renal tissues. However, it remains unclear how cells become 245 
properly differentiated and assembled into vascularized nephrons to produce 246 
urine. But although bioartificial organs generated by decellularization strategies 247 
are associated with massive thrombi, in regenerative medicine this approach 248 




Bioprinting in 3D 253 
 254 
Three-dimensional (3D) bioprinting is based on depositing living cells together 255 
with supporting biomaterials into precise positions to build biological structures 256 
or organs in 3D [58, 59]. However, this technology is still in its infancy and in 257 
order to obtain a whole organ by 3D bioprinting it is necessary to develop novel 258 
supporting biomaterials, which support the growth of living cells, and high 259 
spatial resolution devices that translate into three dimensional complex 260 
geometries the appropriate component to build complex biological structures 261 
composed of vascular and nervous systems [58, 59]. However, studies that 262 
have used this technology to generate structures like vessels, bone, cartilage, 263 
skin, nerves, muscle, adipose tissue and tumours have been published [60].  264 
Nevertheless, the kidney is a spatially heterogeneous organ and for that 265 
reason, fully recapitulating de novo its intricate architecture and complex 266 
composition through scaffold engineering technologies like three-dimensional 267 
bioprinting would be a technically difficult task, if not impossible, with the current 268 
level of technology [61]. The main obstacle to the generation of a kidney is the 269 
current inability to mimic the kidney ECM and deposit the many and various 270 
renal cell types in the correct arrangement [57]. At this point, in accordance with 271 
the previous point is interesting to say that decellularized kidney ECM used as 272 
supporting material could provide a kidney-specific instructional cue to the 273 
printed cells, so that they would behave properly, generating an organ de novo 274 
[15, 57]. However, although this technique is promising, as anything could be 275 
built if the level of technology available were sufficient, there is still a long way 276 
to go. 277 
 278 
 279 
Renal device  280 
 281 
Current renal substitution therapy with haemodialysis or haemofiltration has 282 
been the only successful long-term ex vivo organ substitution therapy to date 283 
[62]. However, the limited removal of metabolic waste products in 284 
kidney patients on dialysis leads to high morbidity and mortality [63]. Between 285 
regenerative medicine and renal replacement therapy, the tissue engineering of 286 
a bioartificial kidney as a renal tubule assist device represents a novel possible 287 
solution to create a structure to replace a kidney function [2, 24]. This device 288 
consists of a bioengineered structure that contains a hybrid "living membrane" 289 
with functional proximal tubule epithelial cells supported by an artificial 290 
functionalized hollow fibre membrane, which demonstrated absorptive, 291 
metabolic, endocrine functions and active organic cation transport [24, 63]. 292 
Renal cells grow in monolayers until confluence and perform different 293 
reabsorption and secretory functions due to the presence of specific active 294 
transporters presents in the living proximal tubule renal cells. Although these 295 
transport functions are less efficient than those in native proximal tubules, it has 296 
been demonstrated that the combination of a synthetic haemofiltration device 297 
and a renal tubule cell therapy device containing porcine renal tubule cells in a 298 
perfusion circuit successfully replaces filtration, transport, metabolic and 299 
endocrine kidney functions in acutely uremic dogs [62]. This technology has 300 
already been the subject of several clinical trials [64, 65], so it could mean that 301 
in a not-too-distant future this technology could be a solution for patients with 302 
end-stage renal disease, given the shortage of kidneys for transplantation. 303 
 304 
Xenoembryos  305 
 306 
Taking advantage of an organogenic niche as a developing embryo, it has been 307 
shown that if stem cells are injected, they can be integrated into the embryo 308 
development programme and become part of the newly generated structures 309 
[24, 39, 48, 54]. Taking advantage of this mechanism, it has been reported that 310 
microinjection of human mesenchymal stem cells (hMSC) into the site where 311 
the metanephros (embryonic kidney) will develop allows these cells to 312 
integrated into the developed metanephros and morphologically differentiated to 313 
tubular epithelial cells, interstitial cells and glomerular epithelial cells [66]. 314 
Recently, it was demonstrated that a xenogeneic foetus can provide a niche in 315 
which hMSC can undergo mesenchymal-to-epithelial transition and 316 
differentiation of nephrons can proceed [48]. During this process the 317 
metanephroi were developed in an embryo that was grown in a whole embryo 318 
culture system after the injection of hMCS [54]. At this point, if metanephroi are 319 
recovered and transplanted into the omentum, the recipient organism develops 320 
a vascular system to connect this embryonic organ, allowing it to grow and form 321 
functional nephrons [67]. Thus, the new kidney formed contains a human 322 
nephron and the vasculature from the host. Furthermore, this neo-kidney was 323 
capable of producing urine by filtering the recipient’s blood and secreted human 324 
erythropoietin in anaemic recipient animals [67]. Through this strategy, whole 325 
functional kidney could be generated from hMSC, although the kidney formed 326 
has a chimeric structure. Nevertheless, in the future it may be possible to 327 
transplant the humanized metanephroi into human omentum, allowing them to 328 
continue to develop and nourish the vascular system generated from human 329 
receptor. Finally, if we used transgenic animals for a suicide-inducible gen, we 330 
would be able to eliminate the xenogeneic tissue [48]. Future studies that use 331 
large animals like pigs might provide a novel direction for regenerating donor 332 
kidneys with a suitable size and function for transplantation [24]. 333 
 334 
 335 
Transplantation of embryonic kidneys 336 
 337 
For years, xenotransplants have been considered as a possible solution to the 338 
organ shortage, but rejection and zoonoses have limited the application of this 339 
kind of treatment [68, 69]. However, transplantation of kidney precursors into 340 
adult hosts showed that intact embryonic kidneys are able to attract the 341 
formation of a vascular system from the host to ensure a blood supply, 342 
undergoing maturation and exhibiting functional properties while avoiding 343 
rejection from non-immunosuppressed hosts [18, 70]. This finding, together with 344 
the production of specific pathogen-free animals [71], could provide a novel 345 
solution for kidney need [18, 72]. As leverage against PSC, metanephros cells 346 
are already committed to a genetic programme of renal development and 347 
"knowing" the destination cell type and how it should be assembled [3], similarly 348 
to if the primordia remained undisturbed within the embryo [73]. It has been 349 
reported that metanephroi of both human and pig origin transplanted into mice 350 
could differentiate into functional nephrons that produce a dilute urine [72]. 351 
Through this strategy, it was reported that survival of total nephrectomized rats 352 
can be increased by prior metanephros transplantation and 353 
ureteroureterostomy [74]. In addition, Yokote et al., reported that if metanephroi 354 
were transplanted beside bladders (developed from cloacae) and this was 355 
connected to the host ureters, hydronephrosis could be avoided and 356 
metanephroi could fully grow, producing and excreting urine through the 357 
recipient ureter [75]. Furthermore, new kidneys developed from metanephroi 358 
provide not only an excretion function, but also an endocrine function, 359 
synthesizing renal hormones like renin and erythropoietin [76, 77]. In rats with 360 
adenine-induced renal failure, the renin activity of metanephroi contributes to 361 
raising arterial blood and suppresses the progression of vascular calcification by 362 
significantly reducing vascular calcium and phosphorus content [78]. 363 
Xenotransplanted embryonic kidney also provides a niche for endogenous 364 
mesenchymal stem cell differentiation into erythropoietin-producing tissue [79]. 365 
In this regard, using metanephroi from suicide-inducible metanephros donors 366 
would enable us to eliminate the xenotissue, leaving only autologous EPO-367 
producing tissue. For this reason, long-term immunosuppression therapies 368 
would not be required and ethical concerns could be mitigated [79].  369 
 370 
One important issue in this field is that the influence of the insertion site of the 371 
kidney is not indifferent. Matsumoto et al. reported that renin production was 372 
greater in metanephroi transplanted into the paraaortic area, where the 373 
developing kidney is exposed to hydrostatic pressure from the aorta, although 374 
there were no site-specific differences in erythropoietin production [77]. To date 375 
metanephroi have been transplanted into different sites such as the anterior eye 376 
chamber [80], intrarenally [80-84], intra-abdominally [85] or intraomentally [84, 377 
86], but all these experiments were performed through open surgery. To our 378 
best knowledge, our recent studies [87-89] were the only experiment to tackle 379 
embryonic kidney transplantation through laparoscopic surgery. In this work, we 380 
developed a new minimally invasive laparoscopic procedure to transfer 381 
metanephroi into the retroperitoneal fat [87-89], where only one endoscope 382 
trocar was inserted into the abdominal cavity and kidney precursor was 383 
aspirated into an epidural catheter that was introduced through the epidural 384 
needle and inserted into the hole performed in fat tissue. Around 50% of rabbit 385 
metanephroi that were allotransplanted through this method grew and 386 
differentiated, presenting normally developed glomeruli, proximal and distal 387 
tubules and collecting ducts [87]. This kind of laparoscopic surgery, rather than 388 
open laparotomy may help move the process to higher animals whose 389 
management is more difficult, but whose nephron structure and size closely 390 
approximate human nephrons [3]. Our group carried out a preliminary study in 391 
goat to provide a better test of the procedure feasibility for clinical application 392 
[90]. Following this protocol, we showed that six weeks post xenotransplantation 393 
of a 15 day-old rabbit metanephros, it grew. 394 
 395 
However, even in a more favourable future situation, where the organ supply 396 
and demand could be balanced using xenotransplants from regenerative 397 
medicine, the ability to physically distribute the organs to patients in need and 398 
produce these organs in a way that allows adequate inventory control and 399 
quality assurance might compromise the technique [88-90]. To this end, organ 400 
cryopreservation will be indispensable and to date, only Bottomley et al. [91] 401 
have evaluated the cryopreservation of whole metanephroi immediately after 402 
thawing, but only under in vitro conditions. Other cryopreservation studies were 403 
performed on human embryonic stem cells, but in these cases the experiments 404 
were performed on individual cells instead of the entire transplantable 405 
metanephros [92, 93]. We recently tested in vivo the effect of long-term 406 
cryopreservation of metanephroi. Briefly, we vitrified metanephroi following the 407 
minimum essential volume method using Cryotop® as device and VM3 as 408 
vitrification solution. This in vitro process showed a survival rate of over 80% of 409 
the metanephros cells. So, when it was transplanted in vivo, similar grown rates 410 
were observed between fresh and vitrified 15-days-old-metanephroi [88], whose 411 
capacity for angiogenesis was preserved. Also in nascent kidneys from vitrified 412 
metanephroi, mature glomeruli were developed, whose histomorphometry 413 
analysis showed that vitrification has no significant effect on glomerular 414 
perimeter, when compared to the corresponding values in the control kidneys. 415 
Furthermore, the expression of renin and erythropoietin were also similar in 416 
vitrified new kidneys and control kidneys. 417 
 418 
If metanephros-developed kidneys could grow large enough to address a 419 
urinary tract connection surgery, transplantation of metanephroi could lead to a 420 
definitive solution to the shortage of kidneys, being an inexhaustible source of 421 
these organs. Therefore, the addition of growth factors or substances that might 422 
favour the angiogenic action of metanephroi, to connect the host vascular 423 






Progress was made toward the ultimate goal of developing functional kidney 430 
grafts in vitro or in vivo on demand. However, kidney regeneration is 431 
considerably more complex than regeneration of other organs due to its 432 
complex functional architecture and the lack of understanding of the molecular 433 
mechanisms underlying stem cell differentiation to renal cells. This review has 434 
summarized the recent research in bioengineering and regenerative medicine 435 
to reconstruct a functional transplantable organ that accomplishes the native 436 
kidney functions. Although many approaches are being implemented in the 437 
different ways outlined in this work, obtaining an organ capable of performing 438 
complex functions such as osmoregulation, excretion or hormone synthesis is 439 
still a long-term goal. In addition, if the artificial kidney is achieved, the organ 440 
must be able to survive and function in the long term. Our group, in addition to 441 
having developed a laparoscopic method for transplanting metanephroi into 442 
large organisms, which can approximate the technique for clinical trials, has 443 
made a substantial contribution to the development of a biobank of kidney 444 
precursors as an unlimited source of kidneys, facilitating sanitary and inventory 445 
control and the distribution of organs. More efforts in the field of bioengineering, 446 
regenerative medicine and biotechnology are necessary to elucidate the 447 
mechanisms able to develop a functional renal structure capable of fulfilling the 448 
functions of a native kidney. The idea is that the long waiting list for a kidney 449 
transplant in patients with end stage renal disease will be eliminated, providing 450 
a definitive solution to these patients. We believe that the efforts in these areas 451 
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